| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Chief Executive Officer
1 company
Stuart Walter Peltz last filed a Form 4 in January 2023, as Chief Executive Officer at PTCT. Stuart Walter Peltz's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Stuart Walter Peltz a middling insider score of 57/100, based on 11 past trades. Over a 12-month horizon, 54.5% of those trades were profitable, with an average 12-month return of +8.1%.
At the last filing, the largest reported position was 54,903 shares of PTCT. The PTCT filings lean toward selling, a net 1,303,377 shares.
Stuart Walter Peltz has 39 Form 4 filings on record from June 2015 to January 2023, all as Chief Executive Officer at Ptc Therapeutics (PTCT), 2015–2023.
The 180 reported transactions were 115 open-market sales, 38 option exercises, 15 option or other derivative awards and 12 stock awards.
Counted by filing, the open-market trades come to no purchases and 29 sales worth about $73.9M.
The largest open-market sale was 348,417 shares of PTCT at an average $61.00 on December 7, 2020, about $21.3M.
Shares as reported in the last Form 4 for each company; the most recent is from January 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 2,621 | $45.63 | $119,590.99 | -4.6% | +20.2% | -43.1% | |
| Jan 24, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 284 | $47.45 | $13,476.17 | -0.5% | +11.8% | -42.4% | |
| Jan 11, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 3,480 | $43.62 | $151,804.77 | -5.9% | +6.1% | -37.1% | |
| Jan 9, 2023 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 2,065 | $41.66 | $86,020.05 | -3.5% | +16.9% | -31.0% | |
| Jun 7, 2022 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 407 | $26.83 | $10,919.00 | -1.1% | +80.5% | +53.6% | |
| Apr 14, 2022 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 82 | $45.28 | $3,712.88 | -0.2% | -0.2% | +10.7% | |
| Feb 1, 2022 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 2,243 | $40.00 | $89,724.49 | -5.5% | -10.7% | +16.9% | |
| Jan 25, 2022 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 330 | $39.31 | $12,973.62 | -0.8% | +2.6% | +18.4% | |
| Jan 7, 2022 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 2,163 | $38.53 | $83,329.58 | -8.8% | +12.9% | +3.2% | |
| Jan 4, 2022 | PTCT Ptc Therapeutics, Inc. | Chief Executive Officer | Sell | 378 | $41.16 | $15,559.24 | -1.6% | +5.9% | -3.4% |